Satsuma Pharmaceuticals takes in $12 mln Series A
Satsuma Pharmaceuticals Inc, which is focused on treating migraines, has raised $12 million Series in A financing. RA Capital Management and TPG Biotech led the round. In conjunction with the funding, Rajeev Shah, RA Capital portfolio manager and managing director and Dr. Heath Lukatch, TPG Biotech partner and managing director, have been added to Satsuma's board of directors.
6 January 2017•1 min read
